Nycomed shoots down Pharmacia rumors

Article

Contrast agent developer Hafslund Nycomed issued a strong denialof rumors circulating last month that Swedish firm Pharmacia wouldmake a bid to buy the Oslo, Norway, company. The rumors originatedin the Oslo stock market, according to Reuters. Nycomed

Contrast agent developer Hafslund Nycomed issued a strong denialof rumors circulating last month that Swedish firm Pharmacia wouldmake a bid to buy the Oslo, Norway, company. The rumors originatedin the Oslo stock market, according to Reuters.

Nycomed and Pharmacia have had no contacts regarding such a buyout,said Eric Cameron, senior vice president of corporate communicationsfor Nycomed.

"The rumor on negotiations or contacts or a declared willor wish from Pharmacia to buy shares or form an alliance withHafslund Nycomed is rumor and contains no reality," Camerontold SCAN. "There has been no contact between the parties."

Cameron said Nycomed did not know the source of the rumor,but said it may have been fueled in part by Nycomed's stated desireto form alliances with other companies in various fields.

"If we can identify possible partners, possible ways ofconducting our business better, we are open for such discussion,"Cameron said. "It doesn't necessarily mean we are sellingourselves. This might have misled people."

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.